Lantheus announces corporate plans, CAD agent strategy

03/24/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said it is undertaking measures to cut costs, including decreasing internal research and development and obtaining a partner for the final development of its PET radiopharmaceutical for diagnosing coronary artery disease, 18F-flurpiridaz. The partner will help with the remainder of Phase III development and commercialization, Lantheus said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC